Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group
Abstract
:1. Introduction
2. Methods
2.1. Expert Panel
2.2. Patient, Disease, Tumor and Previous Treatment Characteristics
- (1)
- Stage IVa disease: easily resectable/ablatable requiring minor hepatectomy and/or ablations;
- (2)
- Stage IVb disease: difficultly resectable/ablatable requiring major hepatectomy (+/– ablations);
- (3)
- Stage IVc disease: initially unresectable/unablatable, but potentially downstageable CRLM where induction systemic therapy and/or future remnant augmentation are appropriate;
- (4)
- Stage IVd disease: permanently unresectable/unablatable CRLM in patients ineligible to receive systemic therapy or after unsuccessful downstaging.
2.3. Study Design
3. Results
3.1. Agreements
Patient Characteristics
3.2. Disease Characteristics
3.3. Tumor Characteristics
3.4. Intertumor or Clustered Dependency Characteristics
3.5. Treatment Characteristics
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- WHO. Estimated Age-Standardized Incidence Rates (World) in 2018, All Cancers, Both Sexes, All Ages. Available online: http://gco.iarc.fr/today/online-analysis-map (accessed on 26 November 2018).
- Engstrand, J.; Nilsson, H.; Stromberg, C.; Jonas, E.; Freedman, J. Colorectal cancer liver metastases—A population-based study on incidence, management and survival. BMC Cancer 2018, 18, 78. [Google Scholar] [CrossRef] [PubMed]
- Hackl, C.; Neumann, P.; Gerken, M.; Loss, M.; Klinkhammer-Schalke, M.; Schlitt, H.J. Treatment of colorectal liver metastases in Germany: A ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer 2014, 14, 810. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kopetz, S.; Chang, G.J.; Overman, M.J.; Eng, C.; Sargent, D.J.; Larson, D.W.; Grothey, A.; Vauthey, J.N.; Nagorney, D.M.; McWilliams, R.R. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 2009, 27, 3677–3683. [Google Scholar] [CrossRef] [PubMed]
- Manfredi, S.; Lepage, C.; Hatem, C.; Coatmeur, O.; Faivre, J.; Bouvier, A.M. Epidemiology and management of liver metastases from colorectal cancer. Ann. Surg. 2006, 244, 254–259. [Google Scholar] [CrossRef] [PubMed]
- Folprecht, G.; Gruenberger, T.; Bechstein, W.O.; Raab, H.R.; Lordick, F.; Hartmann, J.T.; Lang, H.; Frilling, A.; Stoehlmacher, J.; Weitz, J.; et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol. 2010, 11, 38–47. [Google Scholar] [CrossRef]
- Ye, L.C.; Liu, T.S.; Ren, L.; Wei, Y.; Zhu, D.X.; Zai, S.Y.; Ye, Q.H.; Yu, Y.; Xu, B.; Qin, X.Y.; et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J. Clin. Oncol. 2013, 31, 1931–1938. [Google Scholar] [CrossRef] [Green Version]
- Tomasello, G.; Petrelli, F.; Ghidini, M.; Russo, A.; Passalacqua, R.; Barni, S. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients with Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. JAMA Oncol. 2017, 3, e170278. [Google Scholar] [CrossRef]
- Ruers, T.; Punt, C.; Van Coevorden, F.; Pierie, J.P.; Borel-Rinkes, I.; Ledermann, J.A.; Poston, G.; Bechstein, W.; Lentz, M.A.; Mauer, M.; et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: A randomized EORTC Intergroup phase II study (EORTC 40004). Ann. Oncol. 2012, 23, 2619–2626. [Google Scholar] [CrossRef]
- Fiorentini, G.; Sarti, D.; Aliberti, C.; Carandina, R.; Mambrini, A.; Guadagni, S. Multidisciplinary approach of colorectal cancer liver metastases. World J. Clin. Oncol. 2017, 8, 190–202. [Google Scholar] [CrossRef]
- Meijerink, M.R.; Puijk, R.S.; van Tilborg, A.; Henningsen, K.H.; Fernandez, L.G.; Neyt, M.; Heymans, J.; Frankema, J.S.; de Jong, K.P.; Richel, D.J.; et al. Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. Cardiovasc. Intervent. Radiol. 2018, 41, 1189–1204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van Amerongen, M.J.; Jenniskens, S.F.M.; van den Boezem, P.B.; Futterer, J.J.; de Wilt, J.H.W. Radiofrequency ablation compared to surgical resection for curative treatment of patients with colorectal liver metastases—A meta-analysis. HPB (Oxford) 2017, 19, 749–756. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van Tilborg, A.A.; Scheffer, H.J.; de Jong, M.C.; Vroomen, L.G.; Nielsen, K.; van Kuijk, C.; van den Tol, P.M.; Meijerink, M.R. MWA Versus RFA for Perivascular and Peribiliary CRLM: A Retrospective Patient- and Lesion-Based Analysis of Two Historical Cohorts. Cardiovasc. Intervent. Radiol. 2016, 39, 1438–1446. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schicho, A.; Niessen, C.; Haimerl, M.; Wiesinger, I.; Stroszczynski, C.; Beyer, L.P.; Wiggermann, P. Long-term survival after percutaneous irreversible electroporation of inoperable colorectal liver metastases. Cancer Manag. Res. 2019, 11, 317–322. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scheffer, H.J.; Melenhorst, M.C.; Echenique, A.M.; Nielsen, K.; van Tilborg, A.A.; van den Bos, W.; Vroomen, L.G.; van den Tol, P.M.; Meijerink, M.R. Irreversible Electroporation for Colorectal Liver Metastases. Tech. Vasc. Interv. Radiol. 2015, 18, 159–169. [Google Scholar] [CrossRef]
- Scheffer, H.J.; Nielsen, K.; van Tilborg, A.A.; Vieveen, J.M.; Bouwman, R.A.; Kazemier, G.; Niessen, H.W.; Meijer, S.; van Kuijk, C.; van den Tol, M.P.; et al. Ablation of colorectal liver metastases by irreversible electroporation: Results of the COLDFIRE-I ablate-and-resect study. Eur. Radiol. 2014, 24, 2467–2475. [Google Scholar] [CrossRef] [PubMed]
- Mendez Romero, A.; de Man, R.A. Stereotactic body radiation therapy for primary and metastatic liver tumors: From technological evolution to improved patient care. Best. Pract. Res. Clin. Gastroenterol. 2016, 30, 603–616. [Google Scholar] [CrossRef] [PubMed]
- Mahadevan, A.; Blanck, O.; Lanciano, R.; Peddada, A.; Sundararaman, S.; D’Ambrosio, D.; Sharma, S.; Perry, D.; Kolker, J.; Davis, J. Stereotactic Body Radiotherapy (SBRT) for liver metastasis—Clinical outcomes from the international multi-institutional RSSearch(R) Patient Registry. Radiat. Oncol. 2018, 13, 26. [Google Scholar] [CrossRef]
- Scorsetti, M.; Comito, T.; Clerici, E.; Franzese, C.; Tozzi, A.; Iftode, C.; Di Brina, L.; Navarria, P.; Mancosu, P.; Reggiori, G.; et al. Phase II trial on SBRT for unresectable liver metastases: Long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiat. Oncol. 2018, 13, 234. [Google Scholar] [CrossRef] [PubMed]
- Puijk, R.S.; Ruarus, A.H.; Vroomen, L.; van Tilborg, A.; Scheffer, H.J.; Nielsen, K.; de Jong, M.C.; de Vries, J.J.J.; Zonderhuis, B.M.; Eker, H.H.; et al. Colorectal liver metastases: Surgery versus thermal ablation (COLLISION)—A phase III single-blind prospective randomized controlled trial. BMC Cancer 2018, 18, 821. [Google Scholar] [CrossRef] [PubMed]
- Meijerink, M.R. COLLISION XL: Unresectable Colorectal Liver Metastases (3–5cm): Stereotactic Body Radiotherapy vs. Microwave Ablation. Available online: https://clinicaltrials.gov/ct2/show/NCT04081168 (accessed on 20 April 2020).
- Scheffer, H.J.; Vroomen, L.G.; Nielsen, K.; van Tilborg, A.A.; Comans, E.F.; van Kuijk, C.; van der Meijs, B.B.; van den Bergh, J.; van den Tol, P.M.; Meijerink, M.R. Colorectal liver metastatic disease: Efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial). BMC Cancer 2015, 15, 772. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oken, M.M.; Creech, R.H.; Tormey, D.C.; Horton, J.; Davis, T.E.; McFadden, E.T.; Carbone, P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982, 5, 649–655. [Google Scholar] [CrossRef] [PubMed]
- ASA. ASA Physical Status Classification System. Available online: https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system (accessed on 20 April 2020).
- Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic. Dis. 1987, 40, 373–383. [Google Scholar] [CrossRef]
- Guinney, J.; Dienstmann, R.; Wang, X.; de Reynies, A.; Schlicker, A.; Soneson, C.; Marisa, L.; Roepman, P.; Nyamundanda, G.; Angelino, P.; et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015, 21, 1350–1356. [Google Scholar] [CrossRef] [PubMed]
- Fong, Y.; Fortner, J.; Sun, R.L.; Brennan, M.F.; Blumgart, L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann. Surg. 1999, 230, 309–318, discussion 318–321. [Google Scholar] [CrossRef] [PubMed]
- Brudvik, K.W.; Jones, R.P.; Giuliante, F.; Shindoh, J.; Passot, G.; Chung, M.H.; Song, J.; Li, L.; Dagenborg, V.J.; Fretland, A.A.; et al. RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases. Ann. Surg. 2019, 269, 120–126. [Google Scholar] [CrossRef] [PubMed]
- Lawson, E.H.; Gibbons, M.M.; Ko, C.Y.; Shekelle, P.G. The appropriateness method has acceptable reliability and validity for assessing overuse and underuse of surgical procedures. J. Clin. Epidemiol. 2012, 65, 1133–1143. [Google Scholar] [CrossRef]
- Van Cutsem, E.; Cervantes, A.; Adam, R.; Sobrero, A.; Van Krieken, J.H.; Aderka, D.; Aranda Aguilar, E.; Bardelli, A.; Benson, A.; Bodoky, G.; et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016, 27, 1386–1422. [Google Scholar] [CrossRef]
- Kron, P.; Linecker, M.; Jones, R.P.; Toogood, G.J.; Clavien, P.A.; Lodge, J.P.A. Ablation or Resection for Colorectal Liver Metastases? A Systematic Review of the Literature. Front. Oncol. 2019, 9, 1052. [Google Scholar] [CrossRef]
- Brudvik, K.W.; Rosok, B.; Naresh, U.; Yaqub, S.; Fretland, A.A.; Labori, K.J.; Edwin, B.; Bjornbeth, B.A. Survival after resection of colorectal liver metastases in octogenarians and sexagenarians compared to their respective age-matched national population. Hepatobiliary Surg. Nutr. 2018, 7, 234–241. [Google Scholar] [CrossRef]
- Booth, C.M.; Nanji, S.; Wei, X.; Mackillop, W.J. Management and Outcome of Colorectal Cancer Liver Metastases in Elderly Patients: A Population-Based Study. JAMA Oncol. 2015, 1, 1111–1119. [Google Scholar] [CrossRef] [Green Version]
- Grande, R.; Natoli, C.; Ciancola, F.; Gemma, D.; Pellegrino, A.; Pavese, I.; Garufi, C.; Di Lauro, L.; Corsi, D.; Signorelli, D.; et al. Treatment of Metastatic Colorectal Cancer Patients >/=75 Years Old in Clinical Practice: A Multicenter Analysis. PLoS ONE 2016, 11, e0157751. [Google Scholar] [CrossRef] [PubMed]
- Kulik, U.; Framke, T.; Grosshennig, A.; Ceylan, A.; Bektas, H.; Klempnauer, J.; Lehner, F. Liver resection of colorectal liver metastases in elderly patients. World J. Surg. 2011, 35, 2063–2072. [Google Scholar] [CrossRef] [PubMed]
- Rocha, L.; Riechelmann, R.P. Treatment of patients with metastatic colorectal cancer and poor performance status: Current evidence and challenges. Clinics (Sao Paulo) 2018, 73, e542s. [Google Scholar] [CrossRef] [PubMed]
- Sargent, D.J.; Kohne, C.H.; Sanoff, H.K.; Bot, B.M.; Seymour, M.T.; de Gramont, A.; Porschen, R.; Saltz, L.B.; Rougier, P.; Tournigand, C.; et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J. Clin. Oncol. 2009, 27, 1948–1955. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stillwell, A.P.; Ho, Y.H.; Veitch, C. Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J. Surg. 2011, 35, 684–692. [Google Scholar] [CrossRef] [PubMed]
- Chou, W.C.; Liu, K.H.; Lu, C.H.; Hung, Y.S.; Chen, M.F.; Cheng, Y.F.; Wang, C.H.; Lin, Y.C.; Yeh, T.S. To Operate or Not: Prediction of 3-Month Postoperative Mortality in Geriatric Cancer Patients. J. Cancer 2016, 7, 14–21. [Google Scholar] [CrossRef] [Green Version]
- Strandberg Holka, P.; Eriksson, S.; Eberhard, J.; Bergenfeldt, M.; Lindell, G.; Sturesson, C. Significance of poor performance status after resection of colorectal liver metastases. World J. Surg. Oncol. 2018, 16, 3. [Google Scholar] [CrossRef] [Green Version]
- Andres, A.; Toso, C.; Moldovan, B.; Schiffer, E.; Rubbia-Brandt, L.; Terraz, S.; Klopfenstein, C.E.; Morel, P.; Majno, P.; Mentha, G. Complications of elective liver resections in a center with low mortality: A simple score to predict morbidity. Arch. Surg. 2011, 146, 1246–1252. [Google Scholar] [CrossRef] [PubMed]
- Breitenstein, S.; DeOliveira, M.L.; Raptis, D.A.; Slankamenac, K.; Kambakamba, P.; Nerl, J.; Clavien, P.A. Novel and simple preoperative score predicting complications after liver resection in noncirrhotic patients. Ann. Surg. 2010, 252, 726–734. [Google Scholar] [CrossRef] [PubMed]
- Schroeder, R.A.; Marroquin, C.E.; Bute, B.P.; Khuri, S.; Henderson, W.G.; Kuo, P.C. Predictive indices of morbidity and mortality after liver resection. Ann. Surg. 2006, 243, 373–379. [Google Scholar] [CrossRef] [PubMed]
- Tzeng, C.W.; Cooper, A.B.; Vauthey, J.N.; Curley, S.A.; Aloia, T.A. Predictors of morbidity and mortality after hepatectomy in elderly patients: Analysis of 7621 NSQIP patients. HPB (Oxford) 2014, 16, 459–468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Virani, S.; Michaelson, J.S.; Hutter, M.M.; Lancaster, R.T.; Warshaw, A.L.; Henderson, W.G.; Khuri, S.F.; Tanabe, K.K. Morbidity and mortality after liver resection: Results of the patient safety in surgery study. J. Am. Coll. Surg. 2007, 204, 1284–1292. [Google Scholar] [CrossRef] [PubMed]
- Gooiker, G.A.; Dekker, J.W.; Bastiaannet, E.; van der Geest, L.G.; Merkus, J.W.; van de Velde, C.J.; Tollenaar, R.A.; Liefers, G.J. Risk factors for excess mortality in the first year after curative surgery for colorectal cancer. Ann. Surg. Oncol. 2012, 19, 2428–2434. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Simons, J.P.; Ng, S.C.; Hill, J.S.; Shah, S.A.; Bodnari, A.; Zhou, Z.; Tseng, J.F. In-hospital mortality for liver resection for metastases: A simple risk score. J. Surg. Res. 2009, 156, 21–25. [Google Scholar] [CrossRef] [PubMed]
- Kok, E.N.D.; Jansen, E.P.M.; Heeres, B.C.; Kok, N.F.M.; Janssen, T.; van Werkhoven, E.; Sanders, F.R.K.; Ruers, T.J.M.; Nowee, M.E.; Kuhlmann, K.F.D. High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases. Clin. Transl. Radiat. Oncol. 2020, 20, 45–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- He, Z.; Chen, G.; Ouyang, B.; Zhang, H.; Chen, H.; Wang, Y.; Yan, S.; Pan, W. Conformal Radiation Therapy or Stereotactic Body Radiation Therapy: Institutional Experience in the Management of Colorectal Liver Metastases by Radiation Therapy. Technol. Cancer Res. Treat. 2018, 17. [Google Scholar] [CrossRef] [Green Version]
- Guckenberger, M.; Andratschke, N.; Dieckmann, K.; Hoogeman, M.S.; Hoyer, M.; Hurkmans, C.; Tanadini-Lang, S.; Lartigau, E.; Mendez Romero, A.; Senan, S.; et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother. Oncol. 2017, 124, 11–17. [Google Scholar] [CrossRef] [Green Version]
- Friedman, L.S. Surgery in the patient with liver disease. Trans. Am. Clin. Climatol. Assoc. 2010, 121, 192–204; discussion 205. [Google Scholar] [CrossRef]
- Forner, A.; Llovet, J.M.; Bruix, J. Hepatocellular carcinoma. Lancet 2012, 379, 1245–1255. [Google Scholar] [CrossRef]
- Nordlinger, B.; Sorbye, H.; Glimelius, B.; Poston, G.J.; Schlag, P.M.; Rougier, P.; Bechstein, W.O.; Primrose, J.N.; Walpole, E.T.; Finch-Jones, M.; et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008, 371, 1007–1016. [Google Scholar] [CrossRef] [Green Version]
- Nordlinger, B.; Sorbye, H.; Glimelius, B.; Poston, G.J.; Schlag, P.M.; Rougier, P.; Bechstein, W.O.; Primrose, J.N.; Walpole, E.T.; Finch-Jones, M.; et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013, 14, 1208–1215. [Google Scholar] [CrossRef]
- Tanaka, K.; Adam, R.; Shimada, H.; Azoulay, D.; Levi, F.; Bismuth, H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br. J. Surg. 2003, 90, 963–969. [Google Scholar] [CrossRef] [PubMed]
- Adam, R.; de Gramont, A.; Figueras, J.; Kokudo, N.; Kunstlinger, F.; Loyer, E.; Poston, G.; Rougier, P.; Rubbia-Brandt, L.; Sobrero, A.; et al. Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus. Cancer Treat. Rev. 2015, 41, 729–741. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Allen, P.J.; Kemeny, N.; Jarnagin, W.; DeMatteo, R.; Blumgart, L.; Fong, Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J. Gastrointest. Surg. 2003, 7, 109–117. [Google Scholar] [CrossRef]
- Reddy, S.K.; Zorzi, D.; Lum, Y.W.; Barbas, A.S.; Pawlik, T.M.; Ribero, D.; Abdalla, E.K.; Choti, M.A.; Kemp, C.; Vauthey, J.N.; et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: A retrospective multi-institutional analysis. Ann. Surg. Oncol. 2009, 16, 1809–1819. [Google Scholar] [CrossRef]
- Adam, R.; Delvart, V.; Pascal, G.; Valeanu, A.; Castaing, D.; Azoulay, D.; Giacchetti, S.; Paule, B.; Kunstlinger, F.; Ghemard, O.; et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann. Surg. 2004, 240, 644–657; discussion 657–658. [Google Scholar] [CrossRef]
- Folprecht, G.; Gruenberger, T.; Bechstein, W.; Raab, H.R.; Weitz, J.; Lordick, F.; Hartmann, J.T.; Stoehlmacher-Williams, J.; Lang, H.; Trarbach, T.; et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann. Oncol. 2014, 25, 1018–1025. [Google Scholar] [CrossRef]
- Malik, H.; Khan, A.Z.; Berry, D.P.; Cameron, I.C.; Pope, I.; Sherlock, D.; Helmy, S.; Byrne, B.; Thompson, M.; Pulfer, A.; et al. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study. Eur. J. Surg. Oncol. 2015, 41, 499–505. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adam, R.; Pascal, G.; Castaing, D.; Azoulay, D.; Delvart, V.; Paule, B.; Levi, F.; Bismuth, H. Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann. Surg. 2004, 240, 1052–1061; discussion 1061–1064. [Google Scholar] [CrossRef]
- Huiskens, J.; Bolhuis, K.; Engelbrecht, M.R.; De Jong, K.P.; Kazemier, G.; Liem, M.S.; Verhoef, C.; de Wilt, J.H.; Punt, C.J.; van Gulik, T.M.; et al. Outcomes of Resectability Assessment of the Dutch Colorectal Cancer Group Liver Metastases Expert Panel. J. Am. Coll. Surg. 2019, 229, 523–532. [Google Scholar] [CrossRef] [Green Version]
- Brudvik, K.W.; Shindoh, J. Limitations of molecular biomarkers in patients with resectable colorectal liver metastases. Chin. Clin. Oncol. 2019, 8, 48. [Google Scholar] [CrossRef] [PubMed]
- Tsilimigras, D.I.; Ntanasis-Stathopoulos, I.; Bagante, F.; Moris, D.; Cloyd, J.; Spartalis, E.; Pawlik, T.M. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Surg. Oncol. 2018, 27, 280–288. [Google Scholar] [CrossRef] [PubMed]
- Turano, M.; Delrio, P.; Rega, D.; Cammarota, F.; Polverino, A.; Duraturo, F.; Izzo, P.; De Rosa, M. Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy. Cancers (Basel) 2019, 11, 1932. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Allard, M.A.; Adam, R.; Giuliante, F.; Lapointe, R.; Hubert, C.; Ijzermans, J.N.M.; Mirza, D.F.; Elias, D.; Laurent, C.; Gruenberger, T.; et al. Long-term outcomes of patients with 10 or more colorectal liver metastases. Br. J. Cancer 2017, 117, 604–611. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adams, R.B.; Aloia, T.A.; Loyer, E.; Pawlik, T.M.; Taouli, B.; Vauthey, J.N.; Americas Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Selection for hepatic resection of colorectal liver metastases: Expert consensus statement. HPB (Oxford) 2013, 15, 91–103. [Google Scholar] [CrossRef] [Green Version]
- Weiss, M.J.; D’Angelica, M.I. Patient selection for hepatic resection for metastatic colorectal cancer. J. Gastrointest. Oncol. 2012, 3, 3–10. [Google Scholar] [CrossRef] [PubMed]
- Bolton, J.S.; Fuhrman, G.M. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann. Surg. 2000, 231, 743–751. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kanas, G.P.; Taylor, A.; Primrose, J.N.; Langeberg, W.J.; Kelsh, M.A.; Mowat, F.S.; Alexander, D.D.; Choti, M.A.; Poston, G. Survival after liver resection in metastatic colorectal cancer: Review and meta-analysis of prognostic factors. Clin. Epidemiol. 2012, 4, 283–301. [Google Scholar] [CrossRef] [Green Version]
- Scheele, J.; Stangl, R.; Altendorf-Hofmann, A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br. J. Surg. 1990, 77, 1241–1246. [Google Scholar] [CrossRef]
- Stangl, R.; Altendorf-Hofmann, A.; Charnley, R.M.; Scheele, J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994, 343, 1405–1410. [Google Scholar] [CrossRef]
- Adson, M.A.; van Heerden, J.A.; Adson, M.H.; Wagner, J.S.; Ilstrup, D.M. Resection of hepatic metastases from colorectal cancer. Arch. Surg. 1984, 119, 647–651. [Google Scholar] [CrossRef] [PubMed]
- Creasy, J.M.; Sadot, E.; Koerkamp, B.G.; Chou, J.F.; Gonen, M.; Kemeny, N.E.; Balachandran, V.P.; Kingham, T.P.; DeMatteo, R.P.; Allen, P.J.; et al. Actual 10-year survival after hepatic resection of colorectal liver metastases: What factors preclude cure? Surgery 2018, 163, 1238–1244. [Google Scholar] [CrossRef] [PubMed]
- Ruers, T.; Van Coevorden, F.; Punt, C.J.; Pierie, J.E.; Borel-Rinkes, I.; Ledermann, J.A.; Poston, G.; Bechstein, W.; Lentz, M.A.; Mauer, M.; et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J. Natl. Cancer Inst. 2017, 109. [Google Scholar] [CrossRef] [PubMed]
- Lahat, E.; Eshkenazy, R.; Zendel, A.; Zakai, B.B.; Maor, M.; Dreznik, Y.; Ariche, A. Complications after percutaneous ablation of liver tumors: A systematic review. Hepatobiliary Surg. Nutr. 2014, 3, 317–323. [Google Scholar] [CrossRef] [PubMed]
- Liang, P.; Wang, Y.; Yu, X.; Dong, B. Malignant liver tumors: Treatment with percutaneous microwave ablation–complications among cohort of 1136 patients. Radiology 2009, 251, 933–940. [Google Scholar] [CrossRef]
- Takahashi, H.; Berber, E. Role of thermal ablation in the management of colorectal liver metastasis. Hepatobiliary Surg. Nutr. 2020, 9, 49–58. [Google Scholar] [CrossRef] [PubMed]
- Pathak, S.; Jones, R.; Tang, J.M.; Parmar, C.; Fenwick, S.; Malik, H.; Poston, G. Ablative therapies for colorectal liver metastases: A systematic review. Colorectal. Dis. 2011, 13, e252–e265. [Google Scholar] [CrossRef] [PubMed]
- Hof, J.; Wertenbroek, M.W.; Peeters, P.M.; Widder, J.; Sieders, E.; de Jong, K.P. Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases. Br. J. Surg. 2016, 103, 1055–1062. [Google Scholar] [CrossRef] [PubMed]
- Tinguely, P.; Dal, G.; Bottai, M.; Nilsson, H.; Freedman, J.; Engstrand, J. Microwave ablation versus resection for colorectal cancer liver metastases—A propensity score analysis from a population-based nationwide registry. Eur. J. Surg. Oncol. 2020, 46, 476–485. [Google Scholar] [CrossRef]
- Petrelli, F.; Comito, T.; Barni, S.; Pancera, G.; Scorsetti, M.; Ghidini, A.; SBRT for CRC Liver Metastases. Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. Radiother. Oncol. 2018, 129, 427–434. [Google Scholar] [CrossRef]
- Ruarus, A.H.; Vroomen, L.; Puijk, R.S.; Scheffer, H.J.; Zonderhuis, B.M.; Kazemier, G.; van den Tol, M.P.; Berger, F.H.; Meijerink, M.R. Irreversible Electroporation in Hepatopancreaticobiliary Tumours. Can. Assoc. Radiol. J. 2018, 69, 38–50. [Google Scholar] [CrossRef] [PubMed]
- Chang, D.T.; Swaminath, A.; Kozak, M.; Weintraub, J.; Koong, A.C.; Kim, J.; Dinniwell, R.; Brierley, J.; Kavanagh, B.D.; Dawson, L.A.; et al. Stereotactic body radiotherapy for colorectal liver metastases: A pooled analysis. Cancer 2011, 117, 4060–4069. [Google Scholar] [CrossRef] [PubMed]
- Deng, G.; Li, H.; Jia, G.Q.; Fang, D.; Tang, Y.Y.; Xie, J.; Chen, K.F.; Chen, Z.Y. Parenchymal-sparing versus extended hepatectomy for colorectal liver metastases: A systematic review and meta-analysis. Cancer Med. 2019, 8, 6165–6175. [Google Scholar] [CrossRef] [PubMed]
- Philips, P.; Groeschl, R.T.; Hanna, E.M.; Swan, R.Z.; Turaga, K.K.; Martinie, J.B.; Iannitti, D.A.; Schmidt, C.; Gamblin, T.C.; Martin, R.C. Single-stage resection and microwave ablation for bilobar colorectal liver metastases. Br. J. Surg. 2016, 103, 1048–1054. [Google Scholar] [CrossRef] [PubMed]
- Lam, V.W.; Laurence, J.M.; Johnston, E.; Hollands, M.J.; Pleass, H.C.; Richardson, A.J. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford) 2013, 15, 483–491. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nordlinger, B.; Van Cutsem, E.; Rougier, P.; Kohne, C.H.; Ychou, M.; Sobrero, A.; Adam, R.; Arvidsson, D.; Carrato, A.; Georgoulias, V.; et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur. J. Cancer 2007, 43, 2037–2045. [Google Scholar] [CrossRef]
- Crocetti, L.; de Baere, T.; Lencioni, R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc. Intervent. Radiol. 2010, 33, 11–17. [Google Scholar] [CrossRef] [Green Version]
- Mendez Romero, A.; Keskin-Cambay, F.; van Os, R.M.; Nuyttens, J.J.; Heijmen, B.J.M.; JNM, I.J.; Verhoef, C. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep. Pract. Oncol. Radiother. 2017, 22, 126–131. [Google Scholar] [CrossRef] [Green Version]
- Adam, R.; De Gramont, A.; Figueras, J.; Guthrie, A.; Kokudo, N.; Kunstlinger, F.; Loyer, E.; Poston, G.; Rougier, P.; Rubbia-Brandt, L.; et al. The oncosurgery approach to managing liver metastases from colorectal cancer: A multidisciplinary international consensus. Oncologist 2012, 17, 1225–1239. [Google Scholar] [CrossRef] [Green Version]
- Klement, R.J.; Abbasi-Senger, N.; Adebahr, S.; Alheid, H.; Allgaeuer, M.; Becker, G.; Blanck, O.; Boda-Heggemann, J.; Brunner, T.; Duma, M.; et al. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: A combined analysis of 388 patients with 500 metastases. BMC Cancer 2019, 19, 173. [Google Scholar] [CrossRef] [Green Version]
- Hoyer, M.; Roed, H.; Traberg Hansen, A.; Ohlhuis, L.; Petersen, J.; Nellemann, H.; Kiil Berthelsen, A.; Grau, C.; Aage Engelholm, S.; Von der Maase, H. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006, 45, 823–830. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berber, B.; Ibarra, R.; Snyder, L.; Yao, M.; Fabien, J.; Milano, M.T.; Katz, A.W.; Goodman, K.; Stephans, K.; El-Gazzaz, G.; et al. Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB (Oxford) 2013, 15, 851–857. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Andratschke, N.; Alheid, H.; Allgauer, M.; Becker, G.; Blanck, O.; Boda-Heggemann, J.; Brunner, T.; Duma, M.; Gerum, S.; Guckenberger, M.; et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): Patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 2018, 18, 283. [Google Scholar] [CrossRef] [Green Version]
- Dueland, S.; Guren, T.K.; Hagness, M.; Glimelius, B.; Line, P.D.; Pfeiffer, P.; Foss, A.; Tveit, K.M. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann. Surg. 2015, 261, 956–960. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dueland, S.; Syversveen, T.; Solheim, J.M.; Solberg, S.; Grut, H.; Bjornbeth, B.A.; Hagness, M.; Line, P.D. Survival Following Liver Transplantation for Patients with Nonresectable Liver-only Colorectal Metastases. Ann. Surg. 2020, 271, 212–218. [Google Scholar] [CrossRef] [PubMed]
- Smedman, T.M.; Line, P.D.; Hagness, M.; Syversveen, T.; Grut, H.; Dueland, S. Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study). BJS Open 2020, 4, 467–477. [Google Scholar] [CrossRef] [Green Version]
- Hagness, M.; Foss, A.; Line, P.D.; Scholz, T.; Jorgensen, P.F.; Fosby, B.; Boberg, K.M.; Mathisen, O.; Gladhaug, I.P.; Egge, T.S.; et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann. Surg. 2013, 257, 800–806. [Google Scholar] [CrossRef]
- Valdimarsson, V.T.; Hellberg, K.; Brismar, T.B.; Sparrelid, E.; Sturesson, C. Repeat procedures for recurrent colorectal liver metastases: Analysis of long-term liver regeneration and outcome. Cancer Manag. Res. 2019, 11, 2617–2622. [Google Scholar] [CrossRef] [Green Version]
Type I Resection | Type II Thermal ablation RFA/MWA | Type III Non-thermal ablation IRE/SBRT |
---|---|---|
Ia: Unablatable, suitable for resection | IIa: Resectable and ablatable, preference for thermal ablation | IIIa: Unresectable and unablatable, consider IRE or SBRT |
Ib: Resectable and ablatable, preference for resection | IIb: Unresectable, suitable for thermal ablation | IIIb: Unresectable and unablatable, consider SBRT |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nieuwenhuizen, S.; Puijk, R.S.; van den Bemd, B.; Aldrighetti, L.; Arntz, M.; van den Boezem, P.B.; Bruynzeel, A.M.E.; Burgmans, M.C.; de Cobelli, F.; Coolsen, M.M.E.; et al. Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group. Cancers 2020, 12, 1779. https://doi.org/10.3390/cancers12071779
Nieuwenhuizen S, Puijk RS, van den Bemd B, Aldrighetti L, Arntz M, van den Boezem PB, Bruynzeel AME, Burgmans MC, de Cobelli F, Coolsen MME, et al. Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group. Cancers. 2020; 12(7):1779. https://doi.org/10.3390/cancers12071779
Chicago/Turabian StyleNieuwenhuizen, Sanne, Robbert S. Puijk, Bente van den Bemd, Luca Aldrighetti, Mark Arntz, Peter B. van den Boezem, Anna M. E. Bruynzeel, Mark C. Burgmans, Francesco de Cobelli, Marielle M. E. Coolsen, and et al. 2020. "Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group" Cancers 12, no. 7: 1779. https://doi.org/10.3390/cancers12071779
APA StyleNieuwenhuizen, S., Puijk, R. S., van den Bemd, B., Aldrighetti, L., Arntz, M., van den Boezem, P. B., Bruynzeel, A. M. E., Burgmans, M. C., de Cobelli, F., Coolsen, M. M. E., Dejong, C. H. C., Derks, S., Diederik, A., van Duijvendijk, P., Eker, H. H., Engelsman, A. F., Erdmann, J. I., Fütterer, J. J., Geboers, B., ... Meijerink, M. R. (2020). Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group. Cancers, 12(7), 1779. https://doi.org/10.3390/cancers12071779